Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesPRNewsWire • 02/17/21
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021PRNewsWire • 02/16/21
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4PRNewsWire • 02/02/21
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-MarketPRNewsWire • 01/27/21
Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19PRNewsWire • 12/15/20
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-WrapPRNewsWire • 12/09/20
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than ComponentsPRNewsWire • 11/30/20
Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel ConferencePRNewsWire • 11/09/20
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)PRNewsWire • 10/07/20
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 TrialPRNewsWire • 09/29/20
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®PRNewsWire • 09/22/20
Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 CompliancePRNewsWire • 09/15/20
Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment ConferencePRNewsWire • 09/08/20
Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-WrapPRNewsWire • 08/26/20
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional SharesPRNewsWire • 08/10/20
Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 MillionPRNewsWire • 08/06/20
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19PRNewsWire • 07/22/20
Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual EventPRNewsWire • 07/20/20
